• Dr. James J. Koziarz
    Chairman

    James Koziarz brings Rubicon 25 years of experience in the Diagnostics Division of Abbott Laboratories. He served as a corporate officer at Abbott for 12 years. During his career, he managed groups involved in product development, manufacturing and customer technical support, and new technology management. He was involved in the development and introduction of diagnostic products in infectious diseases, endocrinology, cardiology and oncology. He also served as General Manager of two Business Units in the Diagnostics Division.

  • Dr. Roger Newton
    Executive Chairman & CSO, Esperion Therapeutics, Inc.

    Roger Newton has worked for over thirty years in the pharmaceutical and life sciences industries. He is currently Executive Chairman and CSO, and most recently, Founder, President/CEO, and Director of Esperion Therapeutics, Inc., which has its laboratories and offices in the Michigan Life Science and Innovation Center in Plymouth, MI. Prior to these appointments, he was Senior Vice President, Pfizer Global R&D, and Director, Esperion Therapeutics, a Pfizer, Inc. company. He was Co-founder, President/CEO of the original Esperion founded in July 1998. Under Roger’s leadership and the team’s effort, Esperion raised more than $200 million in venture capital and equity financing, building a portfolio of biopharmaceuticals focusing on HDL therapy and small molecule lipid regulating agents. Esperion was acquired by Pfizer for $1.3 billion in February 2004 (13x cash on cash return) and operated as a separate unit within Pfizer until its closure in May 2007. Pfizer then divested Esperion in May 2008 and Roger restarted the company as an independent enterprise with $23 million in venture capital.

    Prior to founding the original Esperion, Roger was with Warner Lambert/Parke-Davis from 1981-1998. As a Distinguished Research Fellow and Chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was the product champion of what is now the most prescribed cholesterol-reducing drug in the world, atorvastatin (Lipitor®).

    Roger’s research interests for the past forty years have focused on the nutritional and pharmacological regulation of cholesterol and lipoprotein metabolism as they relate to cardio-metabolic disease, atherosclerosis, and vascular disease. Roger is an Adjunct Associate Professor in the Department of Pharmacology at the University of Michigan Medical School. He has co-authored nearly ninety peer-reviewed articles and chapters during his research career.  Roger has a Ph.D. in nutrition from the University of California, Davis, a Master of Science degree in nutritional biochemistry from the University of Connecticut, and a Bachelor of Science degree in biology from Lafayette College.

    Roger is a member of the Board of Directors of Juventas Therapeutics, Rubicon Genomics, Ann Arbor Spark, and the Michigan Land Use Institute. He is a member of the National Advisory Boards of the University of Michigan Cardiovascular Center and University of Michigan Life Sciences Institute. He is also a member of the Technology Advisory Boards of Arboretum Ventures, FirstSense Medical, BioSavita, and the Personalized Lifestyle Medicine Institute.

  • Daniel J. Phelps
    Managing Director, Salt Creek Capitol

    Dan Phelps is Managing Director of Salt Creek Capital, a private equity firm. Prior to founding Salt Creek Capital in 2009, Dan was a General Partner at Opus Capital, a venture capital firm formed in 2006, where he targeted growth equity and buyout investments. From 1999 to 2006, he was a General Partner and founding member of Duchossois Technology Partners, a Chicago based venture capital firm. Early in his career, Dan held an investment management position at the Pritzker financial office and began his career at Ernst & Young. He holds a B.S. degree in Business Administration from The Ohio State University and an MBA from the University of Chicago. In addition to serving on our board, Dan serves on the board of Infoblox (NYSE: BLOX) and Fortress International Group (FIGI), and the board of directors of several private companies.

  • Thomas L. Churchwell
    CEO, ViMedicus, Inc.; Managing Partner, Midwest Venture Partners, LLC; Managing Partner, ARCH Development Partners, LLC

    Tom Churchwell is the founder and CEO of ViMedicus, Inc. ViMedicus develops and markets patient centric care coordination solutions. He is Managing Partner of Midwest Venture Partners and of ARCH Development Partners, a subsidiary of the University of Chicago which commercializes technology from the University and Argonne National Laboratory. Previously, he was President and CEO of ARCH Development Corporation. He was  President and CEO of Calgene Fresh, Inc., a 1992 start-up company which produced and marketed the MacGregor’s FLAVR SAVR tomato, the world’s first biotech food product. Prior to joining Calgene Fresh,  Mr. Churchwell was Vice President of ARCH Development Corporation Development and he has held several senior management positions at the NutraSweet Company, including Vice President, Sales and legal positions at G.D. Searle & Co., American Hospital Supply Corporation and The Coca-Cola Export Corporation.

    He holds a BA degree from DePauw University and JD degree from Northwestern University School of Law. He also is a Graduate of the Advanced Management Program at Harvard Graduate School of Business Administration.